IsoRay

IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.

The appointment advances Perspective Therapeutics ' journey to become a global leader in the manufacturing and distribution of therapeutic Cesium-131 brachytherapy radioisotope seeds designed for the treatment of a variety of cancers .

Perspective Therapeutics Expands Management Team And Names Andrew Bright as Executive Vice-President of Brachytherapy

The grant from the Medical Research Council (MRC) of the United Kingdom (part of UK Innovation and Research; UKRI) is supporting preclinical in vitro and in vivo studies of [ 212 Pb]VMT -α -NET for neuroendocrine tumors (NETs)

Perspective Therapeutics Announces the Awarding of a $1 million Collaborative Grant to King's College London to Support Radiobiology Research of Alpha Particle Therapy for Cancer

The result from first patient dosed with VMT-α-NET in India on a compassionate use basis showed favorable responses. The initial response was measured by a somatostatin imaging agent 68Ga-DOTANOC and demonstrated surprisingly favorable results after a single low dose of 212Pb-VMT-a-NET. The result from first patient dosed with VMT-α-NET in India on a compassionate use basis showed favorable responses. The initial response was measured by a somatostatin imaging agent 68Ga-DOTANOC and demonstrated surprisingly favorable results after a single low dose of 212Pb-VMT-a-NET.

Initial Results From First Patient Dosed With Perspective Therapeutics' Lead Drug VMT-α-NET Presented at The Treatment of Neuroendocrine Disorders at the 2023 PET/RTRC Annual Workshop Scientific Session

IsoRay (ISR) delivered earnings and revenue surprises of -100% and 56.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

IsoRay (ISR) Reports Q2 Loss, Misses Revenue Estimates

Fiscal Calendar Year Changes from June to December Year End Fiscal Calendar Year Changes from June to December Year End

Perspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022

C omp any's focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies

Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.

RICHLAND, Wash. & CORALVILLE, Iowa--( BUSINESS WIRE )--Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced the successful completion of the merger with privately-held Viewpoint Molecular Targeting, Inc. The combined companies' focus will be the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies so that precision, targeted medical doses are delivered directly to cancer patient tumor sites. Viewpoint Molecular Targeting CEO Thijs Spoor has been named Chief Executive Officer and outgoing Isoray CEO Lori Woods assumed the role of Chairperson of the Board of Directors of the combined companies. The closing of the all-stock transaction became effective on February 3, 2023.

Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine

Stockholders Approve Proposal One Clearing Way for Consummation of Merger Stockholders Approve Proposal One Clearing Way for Consummation of Merger

Isoray Announces Results of Fiscal 2023 Annual Meeting of Stockholders

RICHLAND, Wash., Jan. 12, 2023 (GLOBE NEWSWIRE) --  Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the January 12th, 2023, adjourned Annual Meeting of Stockholders is being adjourned until January 27th, 2023, to provide stockholders who have not yet voted with additional time to vote on Proposal 1, approval of an amendment to the Company's Certificate of Incorporation to increase the total number of authorized shares of Common Stock. This vote, which requires approval by a majority of the outstanding shares, is required to proceed with the proposed merger with Viewpoint Molecular Targeting, Inc.

Isoray Announces Adjournment of Annual Meeting of Stockholders to January 27, 2023

RICHLAND, Wash., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the December 13th, 2022, Annual Meeting is being adjourned until January 12th, 2023, to provide stockholders with additional time to vote on Proposal 1, approval of an amendment to the Company's Certificate of Incorporation to increase the total number of authorized shares of Common Stock. This vote, which requires approval by a majority of the outstanding shares, is required to proceed with the proposed merger with Viewpoint Molecular Targeting, Inc.

AMENDED: Isoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2023

Isoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2022

NEW ORLEANS--( BUSINESS WIRE )--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Isoray, Inc (“the Company”) (NYSE: ISR) with Viewpoint Molecular Targeting, Inc. pursuant to which Viewpoint shareholders will end up owning 49% of the fully diluted outstanding capital stock of Isoray. KSF is seeking to determine whether the merger and the process that led to it are adequate and fair to the Company's shareholders.

ISORAY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Isoray, Inc - ISR

Isoray, Inc. (NYSE:ISR ) Q1 2023 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Thijs Spoor - CEO, Viewpoint Molecular Targeting Jonathan Hunt - CFO Conference Call Participants Mike Ott - Oppenheimer Operator Good day, ladies and gentlemen. And welcome to the Isoray, Inc. Q1 FY 2023 Call.

Isoray, Inc. (ISR) Q1 2023 Earnings Call Transcript

RICHLAND, Wash., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the first quarter fiscal 2023 ended September 30, 2022 and provided updates regarding the pending merger with Viewpoint Molecular Targeting.

Isoray Announces First Quarter Fiscal 2023 Financial Results and Provides Update to Pending Merger

Conference Call is Thursday, November 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Thursday, November 10, 2022 at 4:30 p.m. ET/1:30 p.m. PT

Isoray To Announce First Quarter Fiscal 2023 Financial Results on November 10, 2022

Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT

Wilmington, Delaware--(Newsfile Corp. - October 3, 2022) - Rigrodsky Law, P.A. is investigating Isoray, Inc. ("Isoray") (NYSE: ISR) regarding possible breaches of fiduciary duties and other violations of law related to Isoray's agreement to merge with Viewpoint Molecular Targeting, Inc.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-isoray-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Isoray, Inc. Merger

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Isoray, Inc. (NYSE: ISR) and Viewpoint Molecular Targeting, Inc. is fair to Isoray shareholders. Halper Sadeh encourages Isoray shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Isoray and its board violated th

ISR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Isoray, Inc. Is Fair to Shareholders

CORALVILLE, IA / ACCESSWIRE / September 29, 2022 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced that it has entered into a definitive agreement to merge with Isoray, Inc (NYSE AMERICAN:ISR), a medical technology company and innovator in seed brachytherapy. Under the terms of the agreement, a newly formed wholly owned subsidiary of Isoray will merge with and into Viewpoint, with Viewpoint continuing as the surviving corporation and a wholly owned subsidiary of Isoray.

Viewpoint Molecular Targeting Announces Transformational Merger

Isoray, Inc. (NYSE:ISR ) Q4 2022 Earnings Conference Call September 28, 2022 4:30 PM ET Company Participants Mark Levin - Investor Relations Lori Woods - Chief Executive Officer Thijs Spoor - Chief Executive Officer, Viewpoint Molecular Targeting Jonathan Hunt - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Mike Ott - Oppenheimer Operator Good afternoon, ladies and gentlemen. And welcome to the Isoray, Inc. Fourth Quarter Fiscal Year 2022 Call.

Isoray, Inc. (ISR) Q4 2022 Earnings Call Transcript

IsoRay (ISR) delivered earnings and revenue surprises of 0% and 13.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

IsoRay (ISR) Reports Q4 Loss, Misses Revenue Estimates

RICHLAND, Wash., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it has entered into a definitive agreement to acquire Viewpoint Molecular Targeting, Inc. (Viewpoint) a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents.

Isoray Announces Transformational Merger and Fourth Quarter and Full-Year Fiscal Year End 2022 Financial Results

Conference Call is Wednesday, September 28 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Wednesday, September 28 at 4:30 p.m. ET/1:30 p.m. PT

Isoray To Announce Fourth Quarter and Fiscal Year End 2022 Financial Results on September 28, 2022

RICHLAND, Wash., June 21, 2022 (GLOBE NEWSWIRE) -- The growing body of information regarding Iso r ay , Inc.'s (NYSE American: ISR) Cesium-131 in treating prostate cancer was highlighted in two presentations at the just concluded American Brachytherapy Society's annual conference in Denver, Colorado.

Isoray's Cesium-131 Featured in Presentations at American Brachytherapy Society's Annual Conference

RICHLAND, Wash., June 15, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a lunch symposium featuring Dr. Stephen J. Frank of the MD Anderson Cancer Center at the American Brachytherapy Society's (ABS) annual conference. The conference is scheduled to take place June 17 – 19 at the Gaylord Rockies Resort in Denver, Colorado.

News for IsoRay Stock (ISR)